Topic
asco
1 stories related to this topic, newest first.
finance10 hrs ago
Ivonescimab Plus Chemotherapy Extends Median Survival by Four Months vs Tislelizumab in Chinese Lung Cancer Trial
Data released Sunday showed ivonescimab reduced death risk by 34 percent versus a PD-1 drug plus chemotherapy. The results are being presented at the ASCO meeting.